New reporting and analysis suggests that many patients using GLP-1 drugs such as Ozempic and Wegovy may be receiving compounded copies rather than brand-name products. Photo checks and pattern tracking reportedly indicated widespread substitution among users. The issue matters for trials, pharmacovigilance, and real-world evidence interpretation because dose, purity, and handling may differ between regulated products and compounded formulations. As shortages have persisted in different periods, the pathway to compounded access has become part of the risk environment for regulators and payers. Biopharma teams preparing post-approval studies and safety monitoring will need to ensure datasets correctly categorize product sources and dosing histories.